Bristol-Myers Squibb (BMY) Tops Q2 EPS by 43c, Beats on Revenue; Offers FY26 Guidance
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $66.82 -1.87%
Revenue Growth %: +3.2%
Financial Fact:
Research and development: 1.14B
Today's EPS Names:
PMCB, CULP, HURC, More
Revenue Growth %: +3.2%
Financial Fact:
Research and development: 1.14B
Today's EPS Names:
PMCB, CULP, HURC, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $2.04, $0.43 better than the analyst estimate of $1.61. Revenue for the quarter came in at $12.97 billion versus the consensus estimate of $11.71 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2026 EPS of $6.75-$7.00, versus the consensus of $6.34. Bristol-Myers Squibb sees FY2026 revenue of $49.5-50 billion, versus the consensus of $47.5 billion.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Dell Technologies (DELL) added to S&P 100 index
- General Dynamics wins $249m in US military contracts
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
